✦ LIBER ✦

Nilotinib and dasatinib first-line: Are we ready for imatinib replacement?

✍ Scribed by Massimo Breccia; Giuliana Alimena

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line treatment for chronic myeloid

✍ Guoqing Wei; Shamudheen Rafiyath; Delong Liu 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 298 KB

First-line treatment of chronic myeloid

✍ Nicholas J. DiBella 📂 Article 📅 2011 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 108 KB

NICE guidance on dasatinib, high-dose im

✍ Scott Goulden; Frances Sutcliffe; Andrew Stevens 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 47 KB

PCN60 Cost Effectiveness of Nilotinib, D

✍ Romero Martin, R.M.; Alvis Nelson, A.N.; De los Ríos Magalí, D.L.R.M.; Chávez Di 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Considerations for early switch to nilot

✍ Quintás-Cardama, Alfonso; Jabbour, Elias J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Cost-Utility Analysis of Dasatinib and N

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB